20 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 20 of 20 clinical reviews.
Find out whether Blue Cross Blue Shield federated plans cover Evenity (romosozumab) for osteoporosis, including prior authorization criteria, step therapy rules, formulary tier, appeal steps, and cost-saving options.
Trial data (ARCH, FRAME) show no significant weight gain or appetite changes with Evenity. See the actual numbers and when to check other causes.
Detailed guide to Humana coverage of Evenity (romosozumab) for osteoporosis, including prior authorization criteria, formulary placement, step therapy rules, appeal pathways, and cost-saving options.
Medicare Advantage plans cover Evenity (romosozumab) under Part B for postmenopausal osteoporosis. Learn about prior authorization, step therapy, appeal options, and out-of-pocket costs.
A clinical review of romosozumab use in patients with autoimmune conditions, covering immunogenicity, drug interactions, cardiovascular signals, and dosing guidance for rheumatologists and endocrinologists.
A MD/PharmD-level review of the cancer risk signal associated with romosozumab (Evenity), including ARCH trial data, FDA label language, post-marketing surveillance findings, and clinical decision frameworks for prescribers.
A detailed clinical review of romosozumab (Evenity) cardiovascular risk, including ARCH trial data, FDA black box warning, post-marketing evidence, and patient selection guidance for severe osteoporosis treatment.
A primary-literature analysis of whether romosozumab (Evenity) affects cognitive function, including sclerostin biology, available trial data, and what patients with osteoporosis should know before starting therapy.
A clinical deep-dive into romosozumab (Evenity) hair loss and skin changes, covering trial data, proposed mechanisms, management strategies, and FDA labeling.
A clinical deep-dive into romosozumab's effect on liver function tests, hepatotoxicity risk, ALT/AST monitoring, and how ARCH trial data and FDA labeling inform prescribing decisions.
A clinical deep-dive into how Evenity (romosozumab) is manufactured, its biologics supply chain, and what is and is not documented about its shortage history since FDA approval.
Evidence-based guide to managing missed doses of Evenity (romosozumab), including clinical recommendations, bone-turnover marker recovery, and how delays affect fracture protection during the 12-month treatment window.
Complete monitoring guide for romosozumab (Evenity) in adults aged 50 to 64. Covers baseline labs, cardiovascular screening, bone turnover markers, calcium management, and month-by-month tracking across all 12 doses.
A clinician-level guide to the complete romosozumab monitoring schedule, baseline labs, on-treatment exams, cardiovascular safety checks, and transition planning after the 12-dose course.
A physician-level guide to the romosozumab pre-surgery hold window, covering ARCH trial data, cardiovascular risk, timing protocols, and return-to-therapy decisions after orthopedic or elective surgery.
Evidence-based review of romosozumab (Evenity) cardiovascular and musculoskeletal safety in geriatric patients aged 65+, including boxed warning context, renal considerations, sequencing after the 12-dose course, and what remains unverified.
Learn whether Evenity (romosozumab) can be self-injected at home, proper subcutaneous injection technique, dose preparation, and what to expect during your 12-month treatment course.
Complete guide to romosozumab (Evenity) storage requirements, temperature stability, shelf life, and handling instructions backed by FDA labeling and peer-reviewed data.
A clinician-level guide to managing romosozumab (Evenity) injections around travel, timezone changes, and missed-dose windows, with primary-literature citations and practical scheduling frameworks.
Evidence-based protocol for discontinuing romosozumab (Evenity) safely, including transition therapy options, bone density monitoring, and fracture prevention after completing 12 monthly doses.